课题基金 / 基金详情

DOXORUBICIN CARDIOTOXICITY IN PATIENTS W/ BREAST CANCER IS PREVENTED BY ICRF 187

DOXORUBICIN CARDIOTOXICITY IN PATIENTS W/ BREAST CANCER IS PREVENTED BY ICRF 187
ICRF 187 可预防乳腺癌患者的阿霉素心脏毒性
批准号：
3843452
负责人：
V J FERRANS
金额：
$0.0万
依托单位：
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/3843452
关键词：
biopsy cardiotoxin cardiovascular disorder prevention combination cancer therapy cyclophosphamide doxorubicin drug adverse effect female fluorouracil human subject human therapy evaluation myocardium myocardium disorder neoplasm /cancer chemotherapy neoplasm /cancer pharmacology

项目摘要

项目成果

V J FERRANS的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Clinical and myocardial biopsy studies were made to evaluate the protective role of ICRF 187 in the prevention of doxorubicin-induced chronic cardiomyopathy in 150 patients with breast cancer who received chemotherapy with doxorubicin, cyclophosphamide and 5-fluorouracil, with or without ICRF 187. The study showed that ICRF provides protection against doxorubicin- induced cardiac toxicity in women with breast cancer without altering the antitumor efficacy of the regimen or adding significantly to its toxicity. Women receiving ICRF 187 were able to receive more cycles and higher cumulative doses of doxorubicin with considerably less cardiac toxicity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
STUDIES OF THE MORPHOLOGY OF THE BIOPROSTHETIC HEART VALVES
SURGICAL PATHOLOGY OF THE CARDIOVASCULAR SYSTEM
ULTRASTRUCTURE AND FUNCTION OF THE MYOCARDIUM--AN OVERVIEW
INTRALUMINAL FIBROSIS IN FIBROTIC LUNG DISORDERS
海外基金